Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 11, 2020

Primary Completion Date

December 27, 2023

Study Completion Date

December 27, 2023

Conditions
Hepatorenal Syndrome
Interventions
DRUG

Terlipressin

"For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump"

Trial Locations (7)

19104

University of Pennsylvania, Philadelphia

30309

Piedmont Healthcare, Inc, Atlanta

37232

Vanderbilt University Medical Center, Nashville

55905

Mayo Clinic, Rochester

76104

Baylor Scott and White All Saints Medical Center, Fort Worth

94114

California Pacific Medical Center, San Francisco

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT04460560 - Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) | Biotech Hunter | Biotech Hunter